Objective | Endpoint |
---|---|
Primary objective | |
Evaluate the long-term safety and tolerability of tezepelumab in patients with severe asthma | Exposure-adjusted incidence of AEs, AESIs and SAEs over 104 weeks |
Secondary objective | |
Assess the long-term effect of tezepelumab on asthma exacerbations in adults and adolescents with severe, uncontrolled asthma, compared with placebo | AAER over 104 weeksa |